RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > California Supreme Court Looks to Take Up 'Pay for Delay' Case

California Supreme Court Looks to Take Up 'Pay for Delay' Case

Posted 05 March 2012 | By Alexander Gaffney, RAC 

The California Supreme Court is set to review a case on so-called 'pay for delay' settlements that see pharmaceutical manufacturers pay generic manufacturers to secure additional months of market exclusivity for their products.

The court will review a decade-old class-action lawsuit against Bayer over its pay for delay settlement to Barr Laboratories. Barr was reportedly planning to sell a generic version of Bayer's antibiotic, Cipro (ciprofloxacin).

The lawsuit alleges that the deal forced Californians to overpay for the drug in violation of California anti-trust law.

The suit follows years of attempts by the Federal Trade Commission (FTC) to ban the practice without success. The Obama administration has proposed to end the practice in its Fiscal Year 2013 budget, but the proposal is far from certain to pass in a Republican-controlled congress.


Read more:

California Watch - State court to examine 'pay-for-delay' deals by drugmakers

Regulatory Focus - Administration Budget Forcefully Against 'Pay-For-Delay,' Industry

 

© 2022 Regulatory Affairs Professionals Society.